High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
about
New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015–December 2015Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.
P2860
High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
High expression of REV7 is an ...... mphoma treated with rituximab.
@en
type
label
High expression of REV7 is an ...... mphoma treated with rituximab.
@en
prefLabel
High expression of REV7 is an ...... mphoma treated with rituximab.
@en
P2093
P2860
P1476
High expression of REV7 is an ...... mphoma treated with rituximab.
@en
P2093
Atsuko Umezawa
Maki Yokoyama
Masaaki Higashihara
Nobuyuki Yanagisawa
Sosei Okina
Yasutaka Sakurai
Yoshiki Murakumo
Yoshiko Numata
P2860
P2888
P304
P356
10.1007/S12185-015-1880-3
P577
2015-10-08T00:00:00Z